Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMVAC Vaccine in Healthy European and Burkinabe Adults
NCT02658253Phase 1Completed
- Sponsor
- Inserm
- Start
- Jan 2016
- Primary completion
- Sep 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of PRIMVAC in malaria (10 arms), sponsored by Inserm. Primary endpoint: Treatment-Related Adverse Events at 35 days. Started Jan 2016; status: completed.
02
Drugs
PRIMVAC
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02658253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658253.